No. of patients colonized with No. of patients acquiring colonization at ICU-discharge with AR-GNB after ICU discharge SDD SOD p-value* SDD SOD p-value* (n=507) (n=489) (n=426) (n=409) At least one ICU A 9/154 35/271 0.02 20/134 42/224 0.35 (5.8%) (12.9%) (14.9%) (18.8.0%) ICU B 7/115 44/124 <0.0001 15/95 19/96 0.47 (6.1%) (35.4%) (15.8%) (19.8%) ICU C 9/238 30/94 <0.0001 24/197 12/89 0.76 (3.8%) (31.9%) (12.2%) (13.5%) All 25/507 109/489 <0.0001 59/426 73/409 0.11 (4.9%) (22.3%) (13.8%) (17.8%) Different AR-GNB 28 131 99 108 10 46 20 36 E.coli 2 17 18 18 Enterobacter sp. 4 11 5 9 Morganella sp. 2 8 7 7 Citrobacter sp. 1 9 6 4 K.pneumoniae 3 15 6 15 P.aeruginosa other 6 25 37 19 Resistance phenotypes Ceftazidime 18 76 55 43 Ciprofloxacin 12 44 19 31 Tobramycin 18 37 32 39 Meropenem 1 5 5 3 Colistin 13 34 31 30 ESBL 7 60 29 24
No. of patients colonized with at ICU-discharge No. of patients acquiring colonization with AR-GNB after ICU discharge SDD (n=507) SOD (n=489) p-value* SDD (n=426) SOD (n=409) p-value* At least one ICU A 9/154 (5.8%) 35/271 (12.9%) 0.02 20/134 (14.9%) 42/224 (18.8.0%) 0.35 ICU B 7/115 (6.1%) 44/124 (35.4%) <0.0001 15/95 (15.8%) 19/96 (19.8%) 0.47 ICU C 9/238 (3.8%) 30/94 (31.9%) <0.0001 24/197 (12.2%) 12/89 (13.5%) 0.76 All 25/507 (4.9%) 109/489 (22.3%) <0.0001 59/426 (13.8%) 73/409 (17.8%) 0.11 Different AR-GNB 28 131 99 108 E.coli 10 46 20 36 Enterobacter sp. 2 17 18 18 Morganella sp. 4 11 5 9 Citrobacter sp. 2 8 7 7 K.pneumoniae 1 9 6 4 P.aeruginosa 3 15 6 15 other 6 25 37 19 Resistance phenotypes Ceftazidime 18 76 55 43 Ciprofloxacin 12 44 19 31 Tobramycin 18 37 32 39 Meropenem 1 5 5 3 Colistin 13 34 31 30 ESBL 7 60 29 24
13054_2018_2170_MOESM2_ESM.docx